J&J’s Zytiga Secures Survival Claim For Early Metastatic Prostate Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling now indicates a statistically significant 19% reduction in risk of death for Zytiga in chemo-naïve metastatic prostate cancer, similar to the 23% reduction just reported in long-term analysis of Medivation/Astellas’ competing Xtandi in the same population.
You may also be interested in...
PREVAIL Impresses, But Prostate Docs Wary Of Declaring Victory For Xtandi Over Zytiga
Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.
Can Zytiga Prevail In Pre-Chemo Prostate Cancer Without Proof Of Survival Benefit?
J&J’s abiraterone gains FDA clearance for the new claim without statistical significance for its 5-month survival advantage, but Medivation’s Xtandi is waiting in the wings – and its pre-chemo trial, PREVAIL, is likely to show a significant effect.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.